Critical role for prokineticin 2 in CNS autoimmunity
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received December 1, 2014
- Accepted in final form February 2, 2015
- First Published April 9, 2015.
Author Disclosures
- Mhamad Abou-Hamdan, PhD,
- Massimo Costanza, PhD,
- Elena Fontana, PhD,
- Marco Di Dario, BS,
- Silvia Musio, PhD,
- Cenzo Congiu, PhD,
- Valentina Onnis, PhD,
- Roberta Lattanzi, PhD,
- Marta Radaelli, MD,
- Vittorio Martinelli, MD,
- Severo Salvadori, MD, PhD,
- Lucia Negri, PhD,
- Pietro Luigi Poliani, MD, PhD,
- Cinthia Farina, PhD,
- Gianfranco Balboni, PhD,
- Lawrence Steinman, MD and
- Rosetta Pedotti, MD, PhD
- Mhamad Abou-Hamdan, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Massimo Costanza, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Elena Fontana, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marco Di Dario, BS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Silvia Musio, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Cenzo Congiu, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Valentina Onnis, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Roberta Lattanzi, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marta Radaelli, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Vittorio Martinelli, MD,
Dr V Martinelli has participated in scientific advisory boards for Merck Serono and Genzyme
NONE
Dr Martinelli has received travel supports and speaker fees for activities with Biogen Idec, Merck/Serono, Bayer, Teva Pharma, Novartis and Genzyme
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Severo Salvadori, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Lucia Negri, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Pietro Luigi Poliani, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Cinthia Farina, PhD,
NONE
NONE
NONE
Since 2013 Editorial Board member of the Journal Advances in Medicine, section Neurology.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Grant support from Merck-Serono
Grant support from Italian Ministry for Health (GR-2009-1607206).
NONE
Grant support from Fondazione Italiana Sclerosi Multipla
NONE
NONE
NONE
NONE
NONE
NONE
- Gianfranco Balboni, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Lawrence Steinman, MD and
NONE
NONE
Biogen, Bayhill, Bayer, Cellgene
MS Journal
I have a patent pending on cytokines and type 1 interferons
NONE
NONE
NONE
EMD Serono
NONE
NONE
JT Pharma, Pfizer, Biogen
NIH $01 55997 2010, 2011
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Rosetta Pedotti, MD, PhD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Italian Ministry of Health, GR-2009-1607206, PI, 2013-2016
NONE
Fondazione Italiana Sclerosi Multipla FISM, FISM 2012/R/13, PI, 2011-2014
NONE
NONE
NONE
NONE
NONE
NONE
- From the Neuroimmunology and Neuromuscular Disorder Unit (M.A.-H., M.C., S.M., R.P.), Neurological Institute Foundation IRCCS Carlo Besta, Milan, Italy; Department of Molecular and Translational Medicine (E.F., P.L.P.), Pathology Unit, University of Brescia, Italy; Institute of Experimental Neurology (M.D.D., M.R., V.M., C.F.), San Raffaele Scientific Institute, Milan, Italy; Department of Life and Environmental Sciences (C.C., V.O., G.B.), Pharmaceutical, Pharmacological and Nutraceutical Sciences Unit, University of Cagliari, Italy; Department of Physiology and Pharmacology Vittorio Erspamer (R.L., L.N.), Sapienza University of Rome, Italy; Department of Chemical and Pharmaceutical Sciences (S.S.), University of Ferrara, Italy; and Department of Neurology (L.S., R.P.), Stanford University School of Medicine, Stanford, CA.
- Correspondence to Dr. Pedotti: rpedotti{at}istituto-besta.it
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.